• Collaborated with cross-functional teams to ensure successful implementation of global study protocols, biomarker programs, data analysis, and publications.• Expert in trial design and protocol development of a Phase I/II clinical trial; critically reviewed trial-related documents.• Performed therapeutic area research and competitor intelligence in hematology for designing combination strategy.• Collaborated with the Data Management team to ensure eCRF design supports data collection in alignment with the protocol, performed database cleaning, Data Review Plan.• Adept at investigator engagement for a global MDS/AML trial and slide preparation for key stakeholders.• Led translational science team in understanding mechanisms of action, target engagement and execute clinical assays for biomarker development.• Single point of contact for maintaining academic collaborations by sponsor research agreements; responsible for analyzing PI research reports and providing comprehensive updates to c-suite.

- Therapeutic Targeting in MDS/AML: Discovered differential splicing of IRAK4 in MDS/AML with U2AF1 and SF3B1 splicing factor mutations (Nat Cell Biology, 2019) (E-Life, 2022).- Determined potential of clinically useful IRAK4 inhibitors (CA-4948) in MDS models resulting in multi-national clinical trial.- Design and analysis of in-vivo drug testing in cell line and patient derived xenograft (PDX) models for clinical drugs.- Analyzed protein-protein interactions and discovered novel molecular target in TLR signaling pathway - CDK2:TRAF6 interaction- Designed, performed and analyzed ex-vivo cellular assays to determine effect of drugs in cell differentiation, proliferation, colony formation and apoptosis.

- Discovered the mechanism of Mcl-1 mediated chemoresistance to BH3 mimetics Navitoclax and Venetoclax.- Determined the clinical potential of targeting BCL-2 family proteins and their interactors- Led projects involving clinical trial drugs that were co-supervised by Abviee (for Navitoclax and Venetoclax) and Pfizer (for Rucaparib) - resulted in 6 peer-reviewed manuscripts.- Developed essential technical skills in molecular biology, streamlined patient sample processing and data management.

– Analyzed various synthetic and natural boronic acid compounds for their effect to antagonize natural autoinducers in Vibrio harveyi quorum sensing pathway.– Assisted in conducting assays for measuring bacterial luminescence at various concentrations of compounds with V. harveyi and calculate their IC50.– Performed assays to check for cytotoxicity of compounds and to test effect of compounds on biofilm formation.– Conducted stability studies of boronic acids in presence of Cu (I) ions using HPLC.

– Expertise in using “Manuscript Central V4.1” a manuscript life cycle product of Scholar One, Inc. for manuscript repositories & processing.– Responsible for processing new as well as revised manuscripts and facilitate communication between editor-in-chief, authors, reviewers and production department.– Maintained accurate database files, assign reviewers, send manuscripts for peer review, prepare correspondence regarding decisions and answer author’s and reviewer’s inquiries.– Dealed with the legal issues associated with manuscripts such as copy right transfer / release agreement.